Development of "super catalytic antibody" against TNF-alpha as a new drug for rheumatoid arthritis.
Project/Area Number |
19360376
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Biofunction/Bioprocess
|
Research Institution | Oita University |
Principal Investigator |
HIFUMI Emi Oita University, 全学研究推進機構, 教授 (90254606)
|
Co-Investigator(Kenkyū-buntansha) |
UDA Taizo 大分大学, 工学部, 教授 (20232837)
|
Project Period (FY) |
2007 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥18,330,000 (Direct Cost: ¥14,100,000、Indirect Cost: ¥4,230,000)
Fiscal Year 2010: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2009: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2008: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2007: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
|
Keywords | 抗体酵素 / 慢性関節リウマチ / TNF-alpha / TNF alpha / リウマチ / germlien gene |
Research Abstract |
Tumor necrosis factor-α TNF-α an inflammatory cytokine and causes several autoimmune diseases such as rheumatoid arthritis, chronic obstructive pulmonary disease etc. Neutralizing antibodies against TNF-α and its receptor have been developed as drugs for rheumatoid arthritis. However, it is noted that bad by-effects such as suppression of physiological function in life have been observed. Therefore, in this study, we challenged to make a highly functional molecule, "super catalytic antibody", which can overcome the drawback of the above drugs. As the result, we successfully produced the "super catalytic antibody" capable of enzymaticaly destroying the human TNF-α.
|
Report
(6 results)
Research Products
(22 results)